21-Gene Assay Associated with Significant Change in Treatment Decisions

Share this content:

the Cancer Therapy Advisor take:

Physicians were more likely to change treatment decisions after evaluating patients using the 21-gene Oncotype DX Assay, according to an article published online in the journal The Oncologist.

Ninety-five patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative early-stage breast cancer (ECB), and node-negative (pN0) disease or micrometastases in up to three lymph nodes (pN1mi) were evaluated regarding their cancer treatments.

Results showed that treatment regimen recommendations changed in 37% of patients, primarily from chemoendocrine to strictly endocrine treatment. The proportion of patients recommended to undergo chemotherapy treatment was also found to decrease from pretest to post-test (52% to 25%, respectively).

After receiving the Oncotype Recurrence Score result, 61% of patients who were originally recommended chemotherapy treatment were newly advised to receive endocrine treatment alone.

Furthermore, physicians’ confidence significantly improved after receiving the Recurrence Score value.

The authors noted that Oncotype DX testing is associated with an overall reduction in chemotherapy use as treatment in patients with ER+, human epidermal growth factor receptor 2-negative EBC, which was consistent with previous studies.

The top inherited genetic loci are likely linked with the development of asparaginase hypersensitivi
Physicians were more likely to change treatment decisions after evaluating patients using the 21-gene Oncotype DX Assay.
The 21-gene Oncotype DX Recurrence Score assay is a validated assay to help decide the appropriate treatment for estrogen receptor-positive (ER+), early-stage breast cancer (EBC) in the adjuvant setting.
READ FULL ARTICLE From theoncologist.alphamedpress.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters